This Webull webinar provides an overview of eXoZymes’ AI-enhanced, cell-free biomanufacturing platform and its ability to manufacture rare natural molecules at industrial scale.

EXOZ Chief Commercial Officer Damien Perriman highlights NCT as the company’s lead proof-of-concept, reviews successful preclinical and manufacturing milestones, and outlines a dual commercialization strategy combining near-term nutraceutical revenues with longer-term pharmaceutical development.

The presentation also discusses the platform’s broader applicability to additional molecule classes, including cannabinoids, upcoming commercialization milestones, and eXoZymes’ strategy to build a repeatable, capital-efficient engine for developing multiple high-value products.